ERIK CABRERA: Open Payments
NPI 1003200395 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$160,648 in 204 payments from 6 companies in 2025. Trend: 2023 $76,292 · 2024 $119,736 · 2025 $160,648
Speaker / faculty: $110,512Consulting: $24,700Travel & lodging: $20,919Food & beverage: $4,518
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 161 | $132,690 |
| Otsuka America Pharmaceutical, Inc. | 23 | $18,551 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $9,059 |
| Teva Pharmaceuticals USA, Inc. | 4 | $136 |
| Alpha Cognition USA, Inc. | 1 | $125 |
| ACADIA Pharmaceuticals Inc | 1 | $87 |
Products named: INGREZZA, REXULTI, CAPLYTA, AUSTEDO XR, Zunveyl, NUPLAZID.
Industry payments across FL — which companies pay providers there.
